JP2025148380A5 - - Google Patents

Info

Publication number
JP2025148380A5
JP2025148380A5 JP2025111263A JP2025111263A JP2025148380A5 JP 2025148380 A5 JP2025148380 A5 JP 2025148380A5 JP 2025111263 A JP2025111263 A JP 2025111263A JP 2025111263 A JP2025111263 A JP 2025111263A JP 2025148380 A5 JP2025148380 A5 JP 2025148380A5
Authority
JP
Japan
Prior art keywords
antibody
seq
drug conjugate
conjugate according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025111263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025148380A (ja
Filing date
Publication date
Priority claimed from JP2024551627A external-priority patent/JP7706668B2/ja
Application filed filed Critical
Publication of JP2025148380A publication Critical patent/JP2025148380A/ja
Publication of JP2025148380A5 publication Critical patent/JP2025148380A5/ja
Pending legal-status Critical Current

Links

JP2025111263A 2022-03-11 2025-07-01 抗体-薬物コンジュゲート及びそれらの使用 Pending JP2025148380A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22305279.6 2022-03-11
EP22305279 2022-03-11
JP2024551627A JP7706668B2 (ja) 2022-03-11 2023-03-10 抗体-薬物コンジュゲート及びそれらの使用
PCT/EP2023/056097 WO2023170247A1 (en) 2022-03-11 2023-03-10 Antibody-drug conjugates and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2024551627A Division JP7706668B2 (ja) 2022-03-11 2023-03-10 抗体-薬物コンジュゲート及びそれらの使用

Publications (2)

Publication Number Publication Date
JP2025148380A JP2025148380A (ja) 2025-10-07
JP2025148380A5 true JP2025148380A5 (cg-RX-API-DMAC7.html) 2026-05-29

Family

ID=80979142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024551627A Active JP7706668B2 (ja) 2022-03-11 2023-03-10 抗体-薬物コンジュゲート及びそれらの使用
JP2025111263A Pending JP2025148380A (ja) 2022-03-11 2025-07-01 抗体-薬物コンジュゲート及びそれらの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024551627A Active JP7706668B2 (ja) 2022-03-11 2023-03-10 抗体-薬物コンジュゲート及びそれらの使用

Country Status (17)

Country Link
US (2) US20250302978A1 (cg-RX-API-DMAC7.html)
EP (2) EP4741423A2 (cg-RX-API-DMAC7.html)
JP (2) JP7706668B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240168351A (cg-RX-API-DMAC7.html)
CN (1) CN119173279A (cg-RX-API-DMAC7.html)
AU (2) AU2023231442B2 (cg-RX-API-DMAC7.html)
CA (1) CA3245732A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002655A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240375A (cg-RX-API-DMAC7.html)
DK (1) DK4489788T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000178A (cg-RX-API-DMAC7.html)
IL (1) IL314828A (cg-RX-API-DMAC7.html)
JO (1) JOP20240199A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011013A (cg-RX-API-DMAC7.html)
PE (1) PE20251386A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023170247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091372A1 (en) * 2022-07-19 2024-03-21 Seoul National University R&Db Foundation Anti-doppel antibody drug conjugates
AU2024263367A1 (en) 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
CN120737008B (zh) * 2025-09-04 2025-11-11 韶远科技(上海)有限公司 一种(S)-4-[2-(Boc-氨基)-1-羟基乙基]-2-硝基苯酚及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
MA50265A (fr) * 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
MX2023011630A (es) * 2021-03-30 2024-01-24 Mablink Bioscience Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas.

Similar Documents

Publication Publication Date Title
TWI923934B (zh) Bcma 單株抗體及抗體藥物結合物
JP2025510629A (ja) カンプトテシンコンジュゲート
FI116038B (fi) Menetelmä lysosomaalientsyymillä pilkottavissa olevien kasvaintenvastaisien lääkeainekonjugaattien valmistamiseksi
TWI735352B (zh) 自行穩定之接合劑共軛物
CN109562170B (zh) 抗cd98抗体及抗体药物偶联物
CA3259758A1 (en) Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
WO2025241603A1 (en) An antibody drug conjugate with opened rings of thiosuccinimides, its preparation and application thereof
BR112019015950A2 (pt) conjugados de anticorpo anti-ccr7 e fármaco
CN117279663A (zh) 一种包括针对人cldn18.2的抗体的抗体药物偶联物及其用途
CN110582505A (zh) 吡咯并苯并二氮杂*缀合物
CN116157417A (zh) 抗体-药物缀合物的制造方法
BR112020008974A2 (pt) conjugados de ligante-fármaco como substratos para clivagem seletiva pela atividade de exopeptidase da catepsina b
HK1255483A1 (zh) 抗体和免疫结合物
BR112021011900A2 (pt) Anticorpos para pmel17 e conjugados dos mesmos
WO2024235130A9 (zh) 多环化合物及其制备方法和用途
US20260021194A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
CN105142664A (zh) 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症
WO2024230755A1 (zh) 一种抗pdl1抗体-药物偶联物及应用
CN120882432A (zh) 抗cd70抗体-药物缀合物
CN120733061A (zh) 包含抗人trop2的抗体的抗体-药物缀合物及其用途
RU2801630C2 (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
RU2826228C2 (ru) Конъюгаты антитело-sting агонист и их применение в иммунотерапии
WO2025214403A1 (zh) 抗体药物偶联物、组合物及其用途和方法
CA3297799A1 (en) Linker-drug molecule and antibody drug conjugate, preparation method therefor and use thereof
KR20250135788A (ko) 세포독성 화합물